Nivolumab for long-term treatment of cHL after auto-HSCT



Micrograph showing HL
Nivolumab can provide long-term treatment for a broad range of adults who have relapsed or refractory classical Hodgkin lymphoma (cHL) after autologous hematopoietic stem cell transplant (auto-HSCT), according to a presentation at the 14th International Conference on Malignant Lymphoma (ICML). In the phase 2 CheckMate-205 study, cHL patients achieved... [Read Article]

Single-dose NEPA found non-inferior to aprepitant/granisetron



Nurse hanging bags
of chemotherapy drugs
Photo by Bill Branson
In a head-to-head study comparing a single-dose oral antiemetic to a 3-day oral regimen, the single dose has shown itself to be non-inferior to the multi-day regimen in preventing chemotherapy-induced nausea and vomiting (CINV). The investigators evaluated netupitant/palonosetron (NEPA) against aprepitant/granisetron (APR/GRAN) in patients on... [Read Article]

Less is more in PET-negative, advanced HL



Cancer patient receiving chemotherapy
Photo by Rhoda Baer
Patients with advanced Hodgkin lymphoma (HL) who are PET-negative after initial treatment with 2 cycles of eBEACOPP* should only receive 2 additional cycles of the therapy, new research suggests. In the HD18 trial, PET-2-negative patients who received 4 cycles of eBEACOPP had non-inferior progression-free survival... [Read Article]

Brentuximab meets phase 3 primary endpoint in frontline advanced HL



Micrograph showing HL
Brentuximab vedotin (Adcetris®) in combination with a 3-drug chemotherapy regimen has met its primary endpoint of statistically significant improvement in modified progression-free survival (mPFS) compared with standard therapy in frontline treatment of advanced stage Hodgkin lymphoma (HL). The ECHELON-1 trial tested brentuximab vedotin plus Adriamycin, vinblastine, and dacarbazine (AVD) against Adriamycin, bleomycin,... [Read Article]

New frontline treatments needed for Hodgkin lymphoma



Anna Sureda, MD, PhD
In this editorial, Anna Sureda, MD, PhD, of the Institut Català d'Oncologia, Hospital Duran i Reynals, in Barcelona, Spain, details the need for new frontline treatments for patients with Hodgkin lymphoma, including those with advanced stage disease. She describes the gap in outcomes with current treatment regimens between patients with early-... [Read Article]